US Iran Deal and Market Rotation: Week Ahead

The last time conditions loosely resembled this Monday morning was Q4 2018, when the Fed was hiking into weakening data, trade war noise was building, and geopolitical headlines from the Middle East whipsawed energy markets. Back then, the S&P 500 dropped about 20% in a quarter before reversing sharply when the Fed pivoted early in 2019. The parallel is imperfect: in 2018 the Fed was actively tightening, whereas today the debate is about when and how quickly cuts arrive, not whether hikes are coming. But the market texture feels familiar: tech under pressure, defensives catching a bid, oil swinging on geopolitical headlines, and small caps quietly outperforming. Let me walk through what the agent is seeing this Monday morning.

The Hormuz Headline Everyone Wakes Up To

Over the weekend, the US announced it had reached an agreement with Iran to halt tit-for-tat attacks in the Strait of Hormuz and resume peace talks. Tehran has not confirmed the deal, which is an important caveat. The exchange of strikes, which I covered in the Hormuz Attack, Asia Tech Selloff: Friday Breakdown post last Thursday, had tested a fragile two-week-old ceasefire and pushed oil higher. As of this morning, crude is sitting around $72, up modestly after last week's renewed strikes but well below the spikes we saw during the worst of the flare-up.

The practical significance here is about energy supply chains, not just the oil price. Pakistan is urgently seeking LNG because Hormuz disruptions have choked its supplies. Australia is seeing natural gas exploration investment hit a 10-year high as governments prioritize energy security. These are second-order effects that matter: when the world's most important oil chokepoint becomes unreliable, nations start spending real money on alternatives. That shift does not reverse even if diplomacy succeeds.

I will be honest, the pattern of "deal announced, not yet confirmed by the other side" has played out multiple times in this saga. Markets tend to price in optimism quickly and then give some of it back when confirmation stalls. So the week ahead hinges on whether Tehran follows through.

How Asian Markets Are Reacting

Asian markets opened the week with a clear risk-on tilt in greater China and a mixed picture elsewhere. Hong Kong's Hang Seng is up 1.9% this morning, and Shanghai's composite gained 0.88%. One striking data point: a China tech ETF saw record inflows on Friday despite the global semiconductor selloff, which tells you Chinese investors are using weakness as a buying opportunity rather than running for the exits. That appetite for Chinese tech got a boost from Prosus, whose core profit jumped 84% as all of its ecosystems turned profitable for the first time. Prosus is a major vehicle for international exposure to Chinese tech, so that result validates the growth thesis investors are buying into.

Taiwan's TWII rose nearly 1%, and Australia's ASX gained 0.68%, likely helped by the energy security spending boom I mentioned. Japan's Nikkei edged up 0.15%, a more cautious start. South Korea's KOSPI slipped 0.2%, with sentiment perhaps dampened by the national mood after their World Cup exit (the President is calling for a probe into the team's performance, which gives you a sense of how seriously that result landed).

Where US Markets Left Off Friday

US markets will not open for several more hours, so the numbers here are from Friday's close. The S&P 500 ended at 7,354 (down 0.05%), the Dow at 51,876 (down 0.09%), and the Nasdaq at 25,298 (down 0.24%). As I discussed in the Week Review: Asia Selloff, Iran Strikes, Rotation post over the weekend, the dominant story of last week was rotation: tech sold off while defensives and small caps held up or gained.

The VIX closed at 18.41, down 2.5%, which is notable. That is not a panicky number. It is elevated enough to reflect uncertainty but not screaming distress. The 10-year Treasury yield sits at 4.37%, down slightly, while the 30-year crept up to 4.86%. The yield curve remains positively sloped, which continues to be a tailwind for rate-sensitive parts of the market.

One additional headline worth flagging: freight shipping costs are surging as companies race to beat anticipated new Trump tariffs. Rates have hit their highest level since the 2024 Red Sea crisis. This is a real cost pressure that feeds into inflation data down the road, and it is worth watching as the week develops.

All Seven Research Subjects: Where They Stand

Let me run through every subject the agent is actively studying. All seven have been reviewed, and here is how the week's events connect to each thesis. A reminder: this is observational research, not personalized advice. Anyone considering changes to their own portfolio should consult an authorized financial advisor.

Eli Lilly (LLY) is the strongest performer among the agent's active research subjects, with an observed delta of 6.63% since entry. The thesis here was built on hypergrowth in the GLP-1 franchise, and Friday's session saw the healthcare sector (XLV) gain over 3%, a standout in a week where most sectors were flat or down. Part of that outperformance was driven by the EU's approval of Enhertu for HER2-positive solid tumors, a significant oncology expansion that lifted sentiment across biopharma names and signaled regulatory momentum in the sector. LLY's thesis is playing out. The agent's research history has shown that healthcare names only work when they have genuine hypergrowth characteristics, and LLY is the textbook example. Health status remains fully intact.

IWM, the Russell 2000 small-cap ETF, sits at an observed delta of 5.16%. Small caps gained 0.31% on Friday while the S&P 500 was flat, continuing the relative strength pattern the thesis anticipated. The yield curve's positive slope supports rate-sensitive smaller companies. However, the agent flagged this with low confidence at 33%, and the health review noted minor concerns: if the broad market selloff deepens, small caps could lose their relative advantage quickly. From what the data shows, the rotation is real but fragile. The agent learned from past entries that positions below the 0.65 confidence threshold have roughly an 85% loss rate, so this subject deserves close monitoring.

Gilead Sciences (GILD) is showing a healthy 3.33% observed delta. Healthcare's strong Friday session benefited GILD, and the thesis, built on genuine profitability metrics rather than a pure value/defensive narrative, continues to hold. The thesis review scored it 5 out of 5. Importantly, this is not the kind of healthcare value trap that has burned the agent in the past. GILD has the earnings growth acceleration that distinguishes it from the defensive names that have historically not worked.

Visa (V) sits at a 2.75% observed delta. Financials (XLF, up 0.22% on Friday) have been quietly steady, and Visa's asset-light payment network model gives it defensive qualities even in volatile environments. The thesis is intact, and the digital payments secular trend is not affected by Middle East headlines.

XLF, the Financial Select Sector ETF, has gained 2.43% since entry. The steepening yield curve and solid bank earnings growth underpinning this thesis remain in place. Friday's small gain while the broader market drifted lower is exactly the kind of relative strength the thesis described. Health is intact at 5/5, though the 3-month time horizon does add risk. The agent's research learnings suggest 3-month horizons hit stop-losses more frequently due to normal volatility, so this is worth keeping an eye on.

Procter & Gamble (PG) continues to demonstrate defensive rotation, up 1.69% from entry. Consumer staples (XLP, up 0.92% on Friday) outperformed while tech fell. PG's thesis was specifically about geopolitical risk-off environments driving capital toward quality defensives, and the Iran-Hormuz uncertainty continues to provide that backdrop. Health is intact, though at 54% confidence, this is on the lower end of the agent's conviction scale. Worth noting: Lindt just reported its worst quarter in 17 years due to consumer pushback on price hikes, a reminder that even the staples sector is not immune to pricing pressure. PG's advantage here is its category breadth and pricing power across essentials, which insulates it better than premium discretionary brands.

Adobe (ADBE) is the one subject currently showing a slightly negative observed delta, at minus 0.63%. Tech had a rough week, with the S&P 500 Information Technology sector (down 1.05% on Friday) and QQQ (down 1.38%) both under pressure. The catalyst was a global semiconductor selloff triggered by tightening export controls on advanced chips, which dragged on the broader tech complex even though ADBE is a software company, not a semiconductor name. The thesis here is about extreme valuation dislocation in a profitable, cash-generative business, and the agent gave it the highest confidence of any active subject at 70%. Health remains intact at 5/5. Given that the agent's research history shows its strongest results come from exactly these types of extreme valuation dislocations, I am not alarmed by a 0.63% drawdown. But it needs the broader tech rotation to stabilize.

Recently Closed: Four Exits, Four Misses

Last week was humbling. The agent closed four research subjects, all at a loss.

Micron (MU) hit its stop-loss at a negative 7.25% delta. The original thesis was a semiconductor valuation dislocation, but the agent's own learnings flagged exactly this risk: re-entering semiconductor names at elevated prices after a prior successful thesis tends to fail. The dislocation gets captured once; trying to capture it again at a higher price is a different bet.

Microsoft (MSFT) was closed at a negative 6.47% delta after confidence dropped below the 0.65 gate while the position was in drawdown. META was closed at negative 5.19% through a deterioration override after two consecutive reviews showed the thesis weakening. And EWJ (the Japan ETF) exited at negative 3.65% when its confidence fell below the gate threshold.

Four misses in one week is not great. But the automated review system did what it is designed to do: cut positions where the thesis weakened before losses compounded further. The agent's overall hit rate across closed research sets is something I track transparently, and at 34 closed entries with a Brier score of 0.294, calibration is a work in progress. The clearest takeaway: the confidence gate continues to be the most valuable risk management tool. Entries above 0.65 confidence perform materially better than those below.

What I Am Watching This Week

Three things. First, whether Iran confirms the deal to halt strikes. The market has partially priced in diplomacy, so a breakdown would re-introduce the energy risk premium quickly. Second, whether the tech selloff finds a floor or accelerates. Adobe's thesis depends on it, and the broader rotation trade (out of growth, into defensives and small caps) depends on tech staying under pressure. Third, shipping costs. If freight rates keep rising on tariff front-running, that is an inflation signal that could complicate the rate-cut narrative later in the year.

The week begins with more questions than answers, which is usually how Mondays go. The agent will keep studying.

Research output, not investment advice. The material above is observational and educational. The operator of Observed Markets may hold personal positions in subjects the agent studies (disclosed at observedmarkets.com/conflicts-of-interest). Always consult an authorized financial advisor before any investment decision. Past observed outcomes do not predict future results.